au en false false Default
HLTHAU VanEck Global Healthcare Leaders ETF Please read important disclosure Close important disclosure false

    • HLTH
    VanEck Global Healthcare Leaders ETF

    HLTH
    VanEck Global Healthcare Leaders ETF

    • NAV
      $11.39

      as at 02-Apr-26
    • Total Net Assets
      $50.77M
    • Dividend Frequency
      1 each year
    • Management fee (p.a.)
      0.45%
    • Number of securities
      50
    • Inception Date
      08-Sep-20
    The NAV is generally calculated daily after all markets are closed for that day based on the closing price of the securities on the relevant foreign stock exchange. The NAV is then converted to AUD based on the relevant London WM Reuters 4pm exchange rate. This means, due to Australia’s time zone, that the NAV will generally not be updated until around 3pm next business day.
    HLTH-VanEck-Global-Healthcare-ETF-Tile.webp

    Overview

    Fund Description

    Our global healthcare ETF, HLTH gives investors exposure to a diversified portfolio of the largest international companies from the global healthcare sector. Our global healthcare ETF aims to provide investment returns, before fees and other costs, which track the performance of the Index. 

    Key benefits

    Global growth opportunity

    A sector with significant growth potential due to shifting global demographics, social changes, research & development and innovation supporting increased demand in healthcare-related products and services.

    A portfolio of global healthcare leaders comprising the most fundamentally strong companies

    Invests in 50 fundamentally sound and attractively valued companies with the best growth prospects in the healthcare sector.

    Targeted exposure and diversification

    A portfolio which targets focused exposure to healthcare and offers true diversification by equally weighting across companies.
      is likely to be appropriate for a consumer who is seeking capital preservation and a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a medium risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 7 years, and has a very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high to very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a major, core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital preservation and a regular income distribution, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a medium risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 7 years, and has an extremely high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a minor or satellite allocation within a portfolio, has no investment timeframe, and has a high or very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking regular income distribution, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a medium risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a satellite allocation within a portfolio, has no minimum investment timeframe, and has an extremely high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a medium risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital preservation and a regular income distribution, is intending to use the product as a standalone solution, major, core, minor or satellite allocation within a portfolio, has no investment timeframe and has a low risk/return profile.

    Index Key points

    Underlying Index

    MarketGrader Developed Markets (ex-Australia) Health Care Index

    Overview

    The Index consists of 50 fundamentally sound companies with the best growth at a reasonable price (GARP) attributes in the healthcare sector from developed markets excluding Australia.

    Summary of Index methodology

    The Index seeks to identify the largest companies in the health care sector with the best growth at a reasonable price (GARP) attributes, being the best drivers of long-term capital appreciation. The Index constituents are selected on the basis of the strength of their fundamentals across four factor categories: growth, value, profitability and cash flow. The 50 Index constituents are equally weighted at each semi-annual rebalance.

    For full details of the methodology, click here.

    Rebalances

    The Index is reviewed and rebalanced on a semi-annual basis, usually as of the close of the third Friday of March and September.

    Index provider

    MarketGrader.com Corporation ('MarketGrader'). MarketGrader is not a related body corporate of VanEck.

    "MarketGrader" and "MarketGrader Developed Markets (Ex-Australia) Health Care Index" are trademarks of MarketGrader.com Corp. and have been licensed for use for certain purposes by VanEck. HLTH is based on the MarketGrader Developed Markets Health Care Net Return AUD Index, but is not sponsored, endorsed, sold or promoted by MarketGrader, and MarketGrader makes no representation regarding the advisability of investing in HLTH.

    Performance

    Holdings & allocations

    All holdings (%) as at 02-Apr-26 Download all holdings

    No. of holdings: 50
    Holding name
    Ticker
    No. of securities held
    		 Market value % of Fund net
    assets
    Kyowa Kirin Co Ltd 4151 JP 47,700 1,139,446 2.24
    Ipsen Sa IPN FP 4,003 1,120,430 2.21
    Arrowhead Pharmaceuticals Inc ARWR US 12,673 1,118,891 2.20
    Astellas Pharma Inc 4503 JP 47,100 1,111,859 2.19
    West Pharmaceutical Services Inc WST US 2,963 1,092,185 2.15
    Illumina Inc ILMN US 5,866 1,080,957 2.13
    Ucb Sa UCB BB 2,442 1,079,334 2.13
    Argenx Se ARGX US 996 1,075,493 2.12
    Exelixis Inc EXEL US 16,917 1,073,878 2.12
    Gsk Plc GSK LN 25,948 1,065,932 2.10
    Astrazeneca Plc AZN SS 3,688 1,064,359 2.10
    United Therapeutics Corp UTHR US 1,301 1,063,028 2.09
    Merck & Co Inc MRK US 6,035 1,055,263 2.08
    Orion Oyj ORNBV FH 8,778 1,051,718 2.07
    Shionogi & Co Ltd 4507 JP 32,600 1,048,777 2.07
    Globus Medical Inc GMED US 8,230 1,046,773 2.06
    Incyte Corp INCY US 7,539 1,046,244 2.06
    Otsuka Holdings Co Ltd 4578 JP 10,100 1,037,863 2.04
    Daiichi Sankyo Co Ltd 4568 JP 39,500 1,035,718 2.04
    Zoetis Inc ZTS US 6,034 1,029,512 2.03
    Alnylam Pharmaceuticals Inc ALNY US 2,226 1,026,778 2.02
    Neurocrine Biosciences Inc NBIX US 5,376 1,023,482 2.02
    Halozyme Therapeutics Inc HALO US 10,959 1,022,418 2.01
    Bristol-Myers Squibb Co BMY US 11,809 1,018,180 2.01
    Johnson & Johnson JNJ US 2,889 1,015,758 2.00
    Teva Pharmaceutical Industries Ltd TEVA IT 23,613 1,009,784 1.99
    Idexx Laboratories Inc IDXX US 1,216 1,001,914 1.97
    Hoya Corp 7741 JP 4,039 1,001,674 1.97
    Alk-Abello A/S ALKB DC 21,754 1,001,111 1.97
    Ypsomed Holding Ag YPSN SW 1,975 999,526 1.97
    Chugai Pharmaceutical Co Ltd 4519 JP 11,910 994,437 1.96
    Stryker Corp SYK US 2,072 993,781 1.96
    Penumbra Inc PEN US 2,075 991,678 1.95
    Samsung Biologics Co Ltd 207940 KS 654 986,636 1.94
    Resmed Inc RMD US 3,022 979,675 1.93
    Encompass Health Corp EHC US 6,951 979,325 1.93
    Dexcom Inc DXCM US 10,860 977,518 1.93
    Novo Nordisk A/S NOVOB DC 18,439 976,787 1.92
    Intuitive Surgical Inc ISRG US 1,478 966,596 1.90
    Alteogen Inc 196170 KS 2,882 965,576 1.90
    Amgen Inc AMGN US 1,905 958,880 1.89
    Eli Lilly & Co LLY US 708 958,251 1.89
    Sk Biopharmaceuticals Co Ltd 326030 KS 10,654 956,256 1.88
    Ensign Group Inc/The ENSG US 3,327 946,336 1.86
    Vertex Pharmaceuticals Inc VRTX US 1,486 943,108 1.86
    Fisher & Paykel Healthcare Corp Ltd FPH NZ 30,872 938,937 1.85
    Insulet Corp PODD US 3,174 938,127 1.85
    Universal Health Services Inc UHS US 3,626 926,892 1.83
    Boston Scientific Corp BSX US 10,092 917,150 1.81
    Tenet Healthcare Corp THC US 3,065 834,345 1.64
    Other/Cash --   84,740 0.17
    Total 100.00
    These are not recommendations to buy or to sell any security.

    Dividends

    Election of Dividend Reinvestment Plan (DRP)

    You can elect DRP by logging into MUFG’s Investor Centre. Once you are logged in, please proceed to the “Payments and Tax” tab and select “Reinvestment Update”.

    Documents & insights

    HLTHAU https://google.com/
    Exchange Traded Funds (ETFs)
    Information about
    Education
    Connect with us